TALPHERA INC (TLPH) Stock Price & Overview
NASDAQ:TLPH • US00444T2096
Current stock price
The current stock price of TLPH is 0.7606 USD. Today TLPH is down by -6.35%. In the past month the price decreased by -6.12%. In the past year, price increased by 52.12%.
TLPH Key Statistics
- Market Cap
- 35.452M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.37
- Dividend Yield
- N/A
TLPH Stock Performance
TLPH Stock Chart
TLPH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TLPH. When comparing the yearly performance of all stocks, TLPH turns out to be only a medium performer in the overall market: it outperformed 61.35% of all stocks.
TLPH Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TLPH. While TLPH seems to be doing ok healthwise, there are quite some concerns on its profitability.
TLPH Earnings
TLPH Forecast & Estimates
8 analysts have analysed TLPH and the average price target is 3.32 USD. This implies a price increase of 335.84% is expected in the next year compared to the current price of 0.7606.
For the next year, analysts expect an EPS growth of 3.51% and a revenue growth -100% for TLPH
TLPH Groups
Sector & Classification
TLPH Financial Highlights
Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 27.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.3% | ||
| ROE | -64.6% | ||
| Debt/Equity | 0 |
TLPH Ownership
TLPH Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.88 | 901.088B | ||
| JNJ | JOHNSON & JOHNSON | 20.47 | 581.222B | ||
| MRK | MERCK & CO. INC. | 23.46 | 303.313B | ||
| PFE | PFIZER INC | 9.02 | 154.837B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.26 | 121.109B | ||
| ZTS | ZOETIS INC | 16.65 | 50.651B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.27 | 27.862B | ||
| VTRS | VIATRIS INC | 5.37 | 15.67B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.99 | 11.664B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.151B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.797B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.066B | ||
| CORT | CORCEPT THERAPEUTICS INC | 50.73 | 4.494B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TLPH
Company Profile
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Company Info
IPO: 2011-02-11
TALPHERA INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA US
Employees: 13
Phone: 16502163500
TALPHERA INC / TLPH FAQ
What does TLPH do?
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
What is the stock price of TALPHERA INC today?
The current stock price of TLPH is 0.7606 USD. The price decreased by -6.35% in the last trading session.
What is the dividend status of TALPHERA INC?
TLPH does not pay a dividend.
What is the ChartMill rating of TALPHERA INC stock?
TLPH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy TLPH stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TLPH.
Can you provide the market cap for TALPHERA INC?
TALPHERA INC (TLPH) has a market capitalization of 35.45M USD. This makes TLPH a Nano Cap stock.
What is the ownership structure of TALPHERA INC (TLPH)?
You can find the ownership structure of TALPHERA INC (TLPH) on the Ownership tab.